Pacira Pharmaceuticals (PCRX) PT Raised to $51 at Piper Jaffray Following Monthly sales Data
Tweet Send to a Friend
Piper Jaffray analyst David Amsellem raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $51.00 (from $48.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
